ProCE Banner Activity

Evolving Treatment Landscape of EGFR-Mutated Advanced and Metastatic NSCLC: Answers to Frequently Asked Questions

Clinical Thought

Read this commentary for experts’ answers to frequently asked questions posed during a live symposium on the evolving therapeutic landscape of patients with advanced EGFR-mutated NSCLC.

Released: June 28, 2024

Expiration: June 27, 2025

Share

Faculty

Nicolas Girard

Nicolas Girard, MD, PhD

Professor
Chair of Medical Oncology
Head of the Thorax Institute Curie-Montsouris
Institut Curie
Universite Paris-Saclay
Paris, France

Natasha Leighl

Natasha Leighl, MD, MMSc, FRCPC, FASCO

Lung Medical Oncology Site Lead
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
Toronto, Canada

Karen Reckamp

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director, Clinical Research
Clinical Professor, Department of Medicine
Cedars-Sinai
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Boehringer Ingelheim Pharmaceuticals, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Disclosure

Primary Author

Nicolas Girard, MD, PhD

Professor
Chair of Medical Oncology
Head of the Thorax Institute Curie-Montsouris
Institut Curie
Universite Paris-Saclay
Paris, France

Nicolas Girard, MD, PhD: researcher: AbbVie, Amgen, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Hoffmann-La Roche, Janssen, LEO Pharma, Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Sanofi, Sivan; consultant: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Hoffmann-La Roche, Ipsen, Janssen, LEO Pharma, Lilly, Merck Sharp & Dohme, Mirati, Novartis, Pfizer, Pierre Fabre, Sanofi, Takeda; data and safety monitoring board: Hoffmann-La Roche.

Natasha Leighl, MD, MMSc, FRCPC, FASCO

Lung Medical Oncology Site Lead
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
Toronto, Canada

Natasha Leighl, MD, MMSc, FRCPC, FASCO: researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Inivata/NeoGenomics, Lilly, Merck Sharp & Dohme, Pfizer; consultant/advisor/speaker: AstraZeneca, Guardant Health, Janssen, Merck Sharp & Dohme, Roche, Sanofi.

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director, Clinical Research
Clinical Professor, Department of Medicine
Cedars-Sinai
Los Angeles, California

Karen Reckamp, MD, MS: consultant/advisor/speaker: Amgen, AstraZeneca, Blueprint, Daiichi Sankyo, EMD Serono, Genentech, GlaxoSmithKline, Janssen, Lilly, Mirati, Novartis; researcher: Blueprint, Calithera, Daiichi Sankyo, Elevation, Genentech, Janssen.